ALK and non-small cell lung carcinoma: The ‘initial survival’ of ALK-rearranged NSCLC in vivo was investigated using an ALC dose of 8 mg/kg/day (2 weeks) because ALK-rearranged tumors had previously shown a sufficient response to ALC at 6 mg/kg4.